You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Mechanism underpinning synergy with combined treatment of MTI-101 and Dexamethasone in Multiple Myeloma
SBC: MODULATION THERAPEUTICS, INC. Topic: NCIABSTRACT Multiple myeloma (MM) is the second most common hematopoietic cancer and while survival rates have slowly increase in the last 10 years, the five-year survival is just over 50%. The high number of patients that become refractory to current therapies is the core reason for the low long-term survival. Therefore, there is a crucial need to develop unique drugs that are active in refractory a ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Enhanced Recovery of Pharmaceutical Solvent driven by EPA Initiative
SBC: COMPACT MEMBRANE SYSTEMS, INC. Topic: NIEHSSummary Enhanced Recovery of Pharmaceutical Solvent driven by EPA InitiativeThe United States Environmental Protection AgencyEPAis establishing new safeguards for hazardous secondary materials with objectives to promote the economicenvironmentaland public health benefits of recycling wasteswith an emphasis on several industrial sectorsincluding the pharmaceutical industryOn averagepharmaceutical m ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis
SBC: GLYCOMIRA, LLC Topic: NIAIDPROJECT SUMMARY Chronic rhinosinusitis (CRS) is one of the most prevalent inflammatory diseases in the U.S., affecting up to 16% of the population and substantially diminishing the quality of life and productivity of patients. In four years, the annual U.S. health care expenditure to treat patients with CRS dramatically increased from $9B to $64B (5% of the health care budget), with a correspondin ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Over-the-Wire Device for Immediate and Complete Peripheral Artery Occlusion
SBC: Artio Medical, Inc Topic: NHLBIABSTRACT Metactive Medical is developing the Blockstent Microcatheteran innovative medical device for endovascular occlusion of peripheral arteries and veinsThe device uses an expandabledetachablegold metal balloon that can be delivered using a highly flexiblelow profileover thewire microcatheteraddressing an unmet medical need for a device that is easy to use and delivers immediatecompleteand las ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Large Pore SPP Particles for Protein Separations
SBC: ADVANCED MATERIALS TECHNOLOGY, INC. Topic: 400AbstractLife sciences research and other critical bioanalytical applications would strongly benefit from faster and higher resolution high performance liquid chromatographicHPLCseparations of larger molecules including proteinspeptidesglycopeptidesand glycansProteins therapeutics are complex moleculessusceptible to intended or unintended alterations of composition and conformationMany therapeutic ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Develop integrated analog photonic modulator components compatible with photonic foundry production
SBC: PHASE SENSITIVE INNOVATIONS INC Topic: AF171126In phase II work, we will collaborate with Prof. Dennis W. Prather in UD and continue to develop broadband, low VÏ€, high linearity, thin-film lithium niobate on insulator (LNOI) modulators that are fully compatible with silicon photonic integrated circuits (PIC) foundry processes. We will demonstrate a low VÏ€, broadband, small footprint LNOI modulator with hybrid Si/LN or SiN/LN waveguide ...
SBIR Phase II 2018 Department of DefenseAir Force -
Novel SCD1 inhibitors for treatment of cancer
SBC: MODULATION THERAPEUTICS, INC. Topic: 102Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Wafer-Level Electronic-Photonic Co-Packaging
SBC: PHASE SENSITIVE INNOVATIONS INC Topic: AF16AT01In phase II work, we will collaborate with Prof. Stefan Preble in RIT and continue to develop large scale hybrid integration and packaging techniques for key active photonic components such as lithium niobate on insulator (LNOI) modulators and modified uni-traveling (MUTC) photodiodes. We will demonstrate a low V, broadband, small footprint LNOI modulator with hybrid Si/LN or SiN/LN waveguide usin ...
STTR Phase II 2018 Department of DefenseAir Force -
Development of an Osteoinductive Spinal Fusion Implant for Enhanced Fusion Rates
SBC: EVOKE MEDICAL LLC Topic: NIAMSPROJECT SUMMARY The objective of this Phase II SBIR is to test the safety and efficacy of an osteoinductive lumbar spinal fusion implant in an ovine modelIn preliminary worklower impedance piezoelectric materials that generate power for direct currentDCelectrical stimulation applications were manufactured and electromechanically characterizedIn an osteoinductive spinal fusion implant designan insu ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Targeting Bioenergetic Flux for Alzheimer's Disease Management
SBC: Aerobyx LLC Topic: NIAPROJECT SUMMARYBioenergetic dysfunction occurs in Alzheimer s diseaseADand represents a potential AD therapeutic targetFor these reasonswe founded AerobyxLLCThe goal of Aerobyx is to develop drugs that specifically target brain bioenergetic fluxesand to use those drugs to treat persons with ADOur strategy emphasizes fundamental biochemical principles such as the law of mass actionand additionally ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health